Athira Pharma FY2023 net loss $117.7M; LIFT-AD enrollment complete; data H2 2024

LeonaBio, Inc.

2023-FY EPS reported -$3.09

Net loss $117.7M ($3.09/sh) vs $95.6M ($2.53/sh) in FY2022; R&D spend rose to $93.8M.
Cash and investments $147.4M as of Dec 31, 2023, down from $245.2M at end of 2022.
Phase 2/3 LIFT-AD trial (fosgonimeton) enrollment completed (~315 pts); topline data expected H2 2024.
First-in-human study of ATH-1105 for ALS on track to initiate in H1 2024.
Adopted 2024 Inducement Plan reserving 750,000 shares; appointed COO/Chief Dev Officer and Chief People Officer.

item 2.02 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

LeonaBio, Inc. reported financial results for the year ended December 31, 2023.

Period: the year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Athira Pharma, Inc. (the “Company”) issued a press release reporting its financial results for the year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-018764

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.